Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

Extensive Metabolic Correction of Hurler Disease By Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II Trial

Bernhard Gentner, MD, Maria Ester Bernardo, MD PhD, Francesca Tucci, MD, Erika Zonari, PhD, Francesca Fumagalli, MD, Silvia Pontesilli, MD, Serena Acquati, PhD, Paolo Silvani, MD, Fabio Ciceri, MD, Attilio Rovelli, MD, Giancarlo La Marca, PhD, Rossella Parini, MD, Silvia Gregori, PhD, Eugenio Montini, PhD, Luigi Naldini, MD PhD, Alessandro Aiuti, MD PhD

Blood (2019) 134 (Supplement_1): 607.

https://doi.org/10.1182/blood-2019-128805

Published: 2019

Journal Articles

TEM-MM-101: A Phase I/IIa Dose Escalation Study Evaluating the Safety and Activity of Autologous CD34+ Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-α2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy

Bernhard Gentner, MD, Francesca Farina, MD, Matteo Giovanni Carrabba, MD, Magda Marcatti, MD, Stefania Girlanda, MD, Gabriele Antonarelli, MD, Capotondo Alessia, PhD, Stefania Mazzoleni, PhD, Carlo Russo, MD, Luigi Naldini, MD PhD, Fabio Ciceri, MD

Blood (2019) 134 (Supplement_1): 2064.

https://doi.org/10.1182/blood-2019-123749

Published: 2019

Journal Articles

Gene Therapy for Beta Thalassemia: Preliminary Results from the PHASE I/II Tiget-Bthal Trial of Autologous Hematopoietic Stem Cells Genetically Modified with GLOBE Lentiviral Vector

Blood (2017) 130 (Supplement 1): 355.

https://doi.org/10.1182/blood.V130.Suppl_1.355.355

Published: 2017

Journal Articles

Reduced Intensity Stem Cell Transplantation Followed By Adjunctive Lenalidomide Is Tolerable and Safe and Improves Complete Response Rate in Multiple Myeloma:a UK NCRI Phase 2 Feasibility Study (LenaRIC)

Mark Cook, MBChB,PhD, Anesh Panchal, BSc, MSc, Kristian Brock, MSc, BSc, Grant McQuaker, MD, John A. Snowden, MD, Charles R Crawley, Hannah Hunter, MB,FRCPath,MRCP, James D Cavenagh, Mirjana Sirovica, BSc(Hons), MSc, Andrea Hodgkinson, BSc(Hons),PhD, Gordon Cook, MD PhD FRCP, FRCPath

Blood (2017) 130 (Supplement 1): 3308.

https://doi.org/10.1182/blood.V130.Suppl_1.3308.3308

Published: 2017

Journal Articles

Plerixafor As a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers (NCT01954914)

Kristina Hoelig, MD, Helmuth Schmidt, MD, Gero Hütter, MD, Michael Kramer, Raphael Teipel, MD, Kristin Zimmer, MD, Matthias Blechschmidt, MD, Tigran Torosian, MD, Rainer Ordemann, MD, Frank Kroschinsky, MD, Alexander H. Schmidt, MD PhD, Martin Bornhäuser, MD, Gerhard Ehninger, MD, Johannes Schetelig, MD MSc

Blood (2016) 128 (22): 3369.

https://doi.org/10.1182/blood.V128.22.3369.3369

Published: 2016

Journal Articles

A Comparative Study of Biosimilar Filgrastim Versus Originator G-CSF for CD34+ Cells Mobilization and Autografting in Hematological Malignancies

Lucia Brunello, Luisa Giaccone, Maria Josè Fornaro, Matilde Scaldaferri, Valter Redoglia, Paola Omedè, PhD, Moreno Festuccia, Giovannino Ciccone, Massimo Massaia, MD, Dario Ferrero, Federica Cavallo, Antonio Palumbo, MD, Francesco Cattel, Andrea Evangelista, Mario Boccadoro, MD, Benedetto Bruno, MD PhD

Blood (2016) 128 (22): 2183.

https://doi.org/10.1182/blood.V128.22.2183.2183

Published: 2016

Journal Articles

Time Dependent Decrease in Efficacy of Second G-CSF Mobilization in Healthy Unrelated Donors

Helmuth Schmidt, MD, Johannes Schetelig, Karin Buhrmann, MD, Anna Kozlova, Gero Hütter, MD, Gerhard Ehninger, MD, Michael Punzel, MD

Blood (2015) 126 (23): 1895.

https://doi.org/10.1182/blood.V126.23.1895.1895

Published: 2015

Journal Articles

Colony Stimulating Factors (Pegfilgrastim or Lenograstim) Use in Patients with Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is Associated with Early Neutrophil Engraftment and Shorter Inpatient Stay with No Impact on Progression Free Survival (PFS) or Overall Survival (OS)

Georgina Mayer, Bhuvan Kishore, MBBS, FRCPATH, MRCP, Richard Lovell, Emmanouil Nikolousis, PhD, Shankaranarayana Paneesha, MD FRCP, FRCPath

Blood (2015) 126 (23): 5450.

https://doi.org/10.1182/blood.V126.23.5450.5450

Published: 2015

Journal Articles

The Impact of Primary Prophylaxis with Granulocyte Colony-Stimulating Factors on Febrile Neutropenia during Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Li Wang, PhD, Onur Baser, PhD, Lucie Kutikova, PhD, John H Page, MD ScD, Richard L Barron, MS

Blood (2014) 124 (21): 4850.

https://doi.org/10.1182/blood.V124.21.4850.4850

Published: 2014

Journal Articles

Prospective Qualitative Study Concerning the Efficiency of PBSC Collections after a Change of Apheresis Device

Marie Y. Detrait, MD, Stephane Morisset, Stat., Jean-Pierre Delville, Arnaud Lixon, Julie Boul, Jean-François Colot, Sabine Meurisse, Odile Bocahut, Philippe Mineur, MD, Margareta Nedelcu, Delphine Pranger, Julien Depaus, Carmela Piacentini, Maryvonne Jurdan, MD, Anne Kornreich, MD, Jean-Luc Canon

Blood (2014) 124 (21): 5834.

https://doi.org/10.1182/blood.V124.21.5834.5834

Published: 2014

Journal Articles

Lower Leukocytosis with Biosimilar Compared with Originator G-CSF during Autologous Stem Cell Mobilization after Chemotherapy in Lymphoma and Multiple Myeloma Patients. a Pharmacovigilance Study of “Rete Ematologica Lombarda” (FARMA-REL)

Anna Maria Pelizzari, MD, Paola Tozzi, PharmD, Francesca Bocchio, Maurizio Bonfichi, Silvia Artuso, Nicola Fracchiolla, MD, Valentino Conti, Pierino Ferremi, Camillo Almici, MD, Daria Bettoni, Vincenza Orlando, PharmD, Giuseppe Rossi, MD, Giuliana Muti

Blood (2014) 124 (21): 5836.

https://doi.org/10.1182/blood.V124.21.5836.5836

Published: 2014

Journal Articles

Successful Stem Cell Mobilization with High-Dose Cytarabine Plus G-CSF after Lenalidomide Therapy for Multiple Myeloma - a Series of Four Cases

Jun Ishiko, MDPhD, Kazuaki Sato, MD, Ruri Kato, MD, Manabu Kawakami, MD PhD, Masashi Nakagawa, Yuzuru Kanakura

Blood (2014) 124 (21): 5831.

https://doi.org/10.1182/blood.V124.21.5831.5831

Published: 2014

Journal Articles

Safety of Peripheral Hematopoietic Stem Cell Mobilization with Lenograstim in Allogeneic Healthy Donors ≥ 50 Years Old: A Single-Centre Experience

Massimo Martino, MD, Antonella Dattola, Roberta Fedele, MD, Antonella Pontari, Tiziana Moscato, MD, Maria Cuzzola, Tiziana Martinello

Blood (2014) 124 (21): 3844.

https://doi.org/10.1182/blood.V124.21.3844.3844

Published: 2014

Journal Articles

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Peter Hillmen, MB ChB, PhD, Donald Milligan, MD, FRCP, FRCPath, Anna Schuh, MD, PhD, Lucy McParland, Anna Chalmers, Tahla Munir, MB ChB, Abraham M Varghese, MB ChB, Andy C Rawstron, BSc, PhD, David J Allsup, MD, PhD, Scott Marshall, MD, Alex Smith, BSc, Corinne Collett, Walter Gregory, PhD, Andrew Duncombe, MD, Dena Cohen, BSc, MSc

Blood (2013) 122 (21): 1639.

https://doi.org/10.1182/blood.V122.21.1639.1639

Published: 2013

Journal Articles

Mobilization Scheme With Cytarabine In Poor Mobilizers Patients Diagnosed With Lymphoma

Cristina Calderón-Cabrera, Magdalena Carmona González, Jesús Martín, Eduardo Ríos Herranz, Pilar Noguerol Novella, Fátima De la Cruz, Estrella Carrillo, Ildefonso Espigado, Jose Antonio Pérez-Simón

Blood (2013) 122 (21): 5440.

https://doi.org/10.1182/blood.V122.21.5440.5440

Published: 2013

Journal Articles

Is Daily Lenograstim From Day +7 Of Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is As Effective As Pegfilgrastim In Patients With Myeloma?

Ben Bailiff, Neil Phillips, Vidhya Murthy, Lynn Bratby, Kathy Holder, Bhuvan Kishore, E Nikolousis, R Lovell, Guy Pratt, Joanne Ewing, Shankaranarayana Paneesha

Blood (2013) 122 (21): 5538.

https://doi.org/10.1182/blood.V122.21.5538.5538

Published: 2013

Journal Articles

Over a Third Of Donors Who Are Smaller Than Their Recipient Fail To Meet The CD34+ Cell Dose Requested For PBSC Transplantation

Annelies Billen, MSc Medicine, J. Alejandro Madrigal, MD, PhD, Bronwen E. Shaw, MBChB, MRCP, PhD, FRCPath

Blood (2013) 122 (21): 4517.

https://doi.org/10.1182/blood.V122.21.4517.4517

Published: 2013

Journal Articles

Factors Influencing Peripheral Blood Progenitor Cell Yield After 2 nd Mobilization With G-CSF In Allogeneic Donors

Kristina Hölig, MD, Michael Kramer, PhD, Kristin Zimmer, MD, Matthias Blechschmidt, MD, Kirsten Poppe-Thiede, MD, Martin Bornhäuser, MD, Gerhard Ehninger, MD

Blood (2013) 122 (21): 3274.

https://doi.org/10.1182/blood.V122.21.3274.3274

Published: 2013

Journal Articles

Use Of Biosimilar G-CSF Compared With Lenograstim In Autologous Haematopoietic Stem Cell Transplant and In Sibling Allogeneic Transplant

Shab Uddin, Pippa Russell, Maresa Farrell, Barbara Davy, Samir G. Agrawal

Blood (2013) 122 (21): 2170.

https://doi.org/10.1182/blood.V122.21.2170.2170

Published: 2013

Journal Articles

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

Blood (2012) 120 (21): 2012.

https://doi.org/10.1182/blood.V120.21.2012.2012

Published: 2012

NARROW

Extensive Metabolic Correction of Hurler Disease By Hematopoietic Stem Cell-Based Gene Therapy: Preliminary Results from a Phase I/II Trial

TEM-MM-101: A Phase I/IIa Dose Escalation Study Evaluating the Safety and Activity of Autologous CD34+ Enriched Hematopoietic Progenitor Cells Genetically Modified for Human Interferon-α2 in Multiple Myeloma Patients with Early Relapse after Intensive Front Line Therapy

Gene Therapy for Beta Thalassemia: Preliminary Results from the PHASE I/II Tiget-Bthal Trial of Autologous Hematopoietic Stem Cells Genetically Modified with GLOBE Lentiviral Vector

Reduced Intensity Stem Cell Transplantation Followed By Adjunctive Lenalidomide Is Tolerable and Safe and Improves Complete Response Rate in Multiple Myeloma:a UK NCRI Phase 2 Feasibility Study (LenaRIC)

Plerixafor As a Salvage Regimen to Mobilize Allogeneic Stem Cells in Healthy Volunteers (NCT01954914)

A Comparative Study of Biosimilar Filgrastim Versus Originator G-CSF for CD34+ Cells Mobilization and Autografting in Hematological Malignancies

Time Dependent Decrease in Efficacy of Second G-CSF Mobilization in Healthy Unrelated Donors

The Impact of Primary Prophylaxis with Granulocyte Colony-Stimulating Factors on Febrile Neutropenia during Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Prospective Qualitative Study Concerning the Efficiency of PBSC Collections after a Change of Apheresis Device

Lower Leukocytosis with Biosimilar Compared with Originator G-CSF during Autologous Stem Cell Mobilization after Chemotherapy in Lymphoma and Multiple Myeloma Patients. a Pharmacovigilance Study of “Rete Ematologica Lombarda” (FARMA-REL)

Successful Stem Cell Mobilization with High-Dose Cytarabine Plus G-CSF after Lenalidomide Therapy for Multiple Myeloma - a Series of Four Cases

Safety of Peripheral Hematopoietic Stem Cell Mobilization with Lenograstim in Allogeneic Healthy Donors ≥ 50 Years Old: A Single-Centre Experience

Results Of The Randomised Phase II NCRI Arctic (Attenuated dose Rituximab with ChemoTherapy In CLL) Trial Of Low Dose Rituximab In Previously Untreated CLL

Mobilization Scheme With Cytarabine In Poor Mobilizers Patients Diagnosed With Lymphoma

Is Daily Lenograstim From Day +7 Of Autologous Peripheral Blood Stem Cell Transplantation (APBSCT) Is As Effective As Pegfilgrastim In Patients With Myeloma?

Over a Third Of Donors Who Are Smaller Than Their Recipient Fail To Meet The CD34+ Cell Dose Requested For PBSC Transplantation

Factors Influencing Peripheral Blood Progenitor Cell Yield After 2 nd Mobilization With G-CSF In Allogeneic Donors

Use Of Biosimilar G-CSF Compared With Lenograstim In Autologous Haematopoietic Stem Cell Transplant and In Sibling Allogeneic Transplant

Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60–75 Years: Protocol-Defined Safety Analysis After 100 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only